AusBiotech is calling for thought leadership articles on innovative approaches, contributions or analyses to include in the April 2022 edition of the Australasian Biotechnology journal.
AusBiotech is welcoming abstracts from valued members on set themes, including investing in medical technology (devices and diagnostics), robotics, mRNA, and medtech regulation.
The journal will also feature a sneak peek into the AusMedtech 2022, AusBiotech’s premier medtech conference taking place on 24-26 May, where key stakeholders of the Australian and international devices and diagnostics sector engage and challenge the status quo as they drive the sector forward.
Australasian Biotechnology is AusBiotech’s official biannual journal and published in April and October. Its contributions are written by the sector, for the sector.
With its informed and authoritative editorials, Australasian Biotechnology is a highly-effective communications vehicle for those wanting to reach out to stakeholders in the life sciences sector. The journal is mailed on a name-and-title basis to over 3,000 AusBiotech members and investors, as well as published digitally. Readership includes companies, government and university departments, research institutes, biotechnology and professional services providers nationally, and in key overseas markets.
Two-hundred word abstracts on your proposed topic can be sent to the AusBiotech Communications team by 17 December 2021.
If your abstract is accepted, the full article will be required on or before 4 February 2022. Article lengths are approximately 500 words (1 page) or 1,000 words (2 pages). High-resolution photos to accompany articles are encouraged.
Articles are a member-benefit, however there is limited space and so are not guaranteed to be included. Abstracts are welcomed on research, business news, and sector trends for consideration at any time of the year.